Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study

[1]  J. Rosenbaum,et al.  Management of Comorbidities in Ankylosing Spondylitis , 2012, The American journal of the medical sciences.

[2]  M. Hedberg,et al.  Calprotectin in ankylosing spondylitis – frequently elevated in feces, but normal in serum , 2012, Scandinavian journal of gastroenterology.

[3]  M. Punaro,et al.  Fecal Calprotectin in Children with the Enthesitis-related Arthritis Subtype of Juvenile Idiopathic Arthritis , 2011, Journal of Rheumatology.

[4]  Paul Weston,et al.  Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility , 2011, Nature Genetics.

[5]  D. Elewaut,et al.  Mucosal Inflammation in Spondylarthritides: Past, Present, and Future , 2011, Current rheumatology reports.

[6]  J. Taurog.  The Role of HLA-B27 in Spondyloarthritis , 2010, The Journal of Rheumatology.

[7]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[8]  Michael Weisman,et al.  Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease , 2010, PLoS genetics.

[9]  D. Elewaut,et al.  Interactions between gut inflammation and arthritis/spondylitis , 2010, Current opinion in rheumatology.

[10]  Christian Gieger,et al.  Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL) , 2010, Nature Genetics.

[11]  S. Targan,et al.  Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study , 2009, Arthritis research & therapy.

[12]  Toshio Watanabe,et al.  Present status and strategy of NSAIDs-induced small bowel injury , 2009, Journal of Gastroenterology.

[13]  W. Fries,et al.  Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. , 2009, World journal of gastroenterology.

[14]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[15]  H. Direskeneli,et al.  Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. , 2008, Rheumatology.

[16]  B. Thjódleifsson,et al.  A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. , 2007, Arthritis and rheumatism.

[17]  S. Targan,et al.  Anti‐flagellin (CBir1) phenotypic and genetic Crohn's disease associations , 2007, Inflammatory bowel diseases.

[18]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[19]  J. Reveille,et al.  Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort , 2006, Annals of the rheumatic diseases.

[20]  L. Denson,et al.  Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[21]  J. Ragoussis,et al.  Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. , 2005, Human molecular genetics.

[22]  S. Targan,et al.  Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. , 2005, Gastroenterology.

[23]  J. Glas,et al.  Inflammatory Bowel Disease-Specific Autoantibodies in HLA-B27-Associated Spondyloarthropathies: Increased Prevalence of ASCA and pANCA , 2004, Digestion.

[24]  S. Bombardieri,et al.  Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. , 2004, The Journal of rheumatology.

[25]  P. Emery,et al.  Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis , 2003, Annals of the rheumatic diseases.

[26]  Jonathan Braun,et al.  Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. , 2002, Gastroenterology.

[27]  D. Baeten,et al.  Ankylosing spondylitis and bowel disease. , 2002, Best practice & research. Clinical rheumatology.

[28]  S. Bunn,et al.  Fecal Calprotectin as a Measure of Disease Activity in Childhood Inflammatory Bowel Disease , 2001, Journal of pediatric gastroenterology and nutrition.

[29]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[30]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[31]  M. De Vos,et al.  Bowel inflammation and the spondyloarthropathies. , 1998, Rheumatic diseases clinics of North America.

[32]  S. Targan,et al.  Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.

[33]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[34]  M. De Vos,et al.  The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. , 1995, The Journal of rheumatology.

[35]  M. De Vos,et al.  The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. , 1995, The Journal of rheumatology.

[36]  J. Cantero-Hinojosa,et al.  Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. , 1994, British journal of rheumatology.

[37]  M. De Vos,et al.  Ileocolonoscopic findings in seronegative spondylarthropathies. , 1988, British Journal of Rheumatology.

[38]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[39]  H. Mielants,et al.  Inflammatory Bowel Disease Spondyloarthritis: Epidemiology, Clinical Features, and Treatment , 2006 .

[40]  P. Rutgeerts,et al.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. , 1999, Gastroenterology.

[41]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[42]  M. Leirisalo-Repo,et al.  High frequency of silent inflammatory bowel disease in spondylarthropathy. , 1994, Arthritis and rheumatism.